Overview
- The study in Med tested intrarectal administration of non‑oxygenated perfluorodecalin for 60 minutes in 27 healthy male volunteers.
- No serious adverse events were observed, with mild, transient bloating the most common complaint and vital signs remaining stable.
- Doses up to 1,000 mL were deemed tolerable; some participants receiving higher volumes reported discomfort, and seven did not complete the full hour.
- The trial evaluated safety only, so whether the method can raise blood oxygen levels in humans remains unproven.
- Investigators plan Phase II trials of oxygenated perfluorodecalin with clinical partners in Japan and the United States as a potential bridge therapy for respiratory failure.